Improved Ability to Perform Strenuous Activities After Treatment with Fluticasone Propionate/Salmeterol Combination in Patients with Persistent Asthma

By Nathan Robert A.   Dorinsky Paul   Carranza Rosenzweig Jacqueline R.   Shah Tushar   Edin Heather   Prillaman Barbara  

Journal of Asthma, Vol. 40, Iss. 7, 2003-01 ,pp. : 815-822

Informa Healthcare

Access to resources Recommend Favorite

Body Mass Index and Response to Asthma Therapy: Fluticasone Propionate/Salmeterol versus Montelukast

By Camargo Carlos A.   Boulet Louis-Philippe   Sutherland E. Rand   Busse William W.   Yancey Steven W.   Emmett Amanda H.   Ortega Hector G.   Ferro Thomas J.  

Journal of Asthma, Vol. 47, Iss. 1, 2010-02 ,pp. : 76-82

Informa Healthcare

Access to resources Recommend Favorite

Retrospective Comparison of Early versus Late Treatment with Fluticasone Propionate//Salmeterol After an Asthma Exacerbation

By Hagiwara May   Delea Thomas E.   Stanford Richard H.  

Journal of Asthma, Vol. 48, Iss. 7, 2011-09 ,pp. : 721-728

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of Fluticasone Propionate/Salmeterol HFA 134A MDI in Patients with Mild‐to‐Moderate Persistent Asthma

By Pearlman David   Peden David   Condemi John   Weinstein Steven   White Martha   Baitinger Leslie   Scott Catherine   Ho Shu   House Karen   Dorinsky Paul  

Journal of Asthma, Vol. 41, Iss. 8, 2004-01 ,pp. : 797-806

Informa Healthcare

Access to resources Recommend Favorite

Risk of Asthma Exacerbation, Asthma-Related Health Care Utilization and Costs, and Adherence to Controller Therapy in Patients with Asthma Receiving Fluticasone Propionate/Salmeterol Inhalation Powder 100 μg/50 μg Versus Mometasone Furoate Inhalation Powder

By Hagiwara May  

Journal of Asthma, Vol. 50, Iss. 3, 2013-04 ,pp. : 287-295

Informa Healthcare

Access to resources Recommend Favorite